Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: A retrospective review from a tertiary referral center.

Bone Marrow Transplantation

Volumn 48, Issue 10, 2013, Pages 1302-1307

  Dispenzieri, A ^a   Seenithamby, K ^a   Lacy, M Q ^a   Kumar, S K ^a   Buadi, F K ^a   Hayman, S R ^a   Dingli, D ^a   Litzow, M R ^a   Gastineau, D A ^a   Inwards, D J ^a   Micallef, I N ^a   Ansell, S M ^a   Johnston, P B ^a   Porrata, L F ^a   Patnaik, M M ^a   Hogan, W J ^a   Gertz, M A A ^a  

^a MAYO CLINIC   (United States)

Author keywords

amyloidosis; myeloma; response; survival prediction

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; IMMUNOGLOBULIN LIGHT CHAIN; LACTATE DEHYDROGENASE; M PROTEIN; MELPHALAN; PROTEIN;

ADULT; AGED; AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMACYTOSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; REVIEW; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; TERTIARY HEALTH CARE; TIME TO TREATMENT; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BODY RADIATION;

ADULT; AGED; AMYLOIDOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84885660451     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.53     Document Type: Review

References (41)

1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
2. Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev 2012; 26: 137-154.
3. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108: 2520-2530.
4. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87: 78-88.
5. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 180-186.
6. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S et al. Discordance between serum cardiac biomarker and immunoglobulin-free lightchain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 2010; 85: 757-759.
7. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer S, Witzig TE, Fonseca R et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003; 10: 257-261. (Pubitemid 38117510)
8. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766-769. (Pubitemid 28308529)
9. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011; 86: 12-18.
10. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
11. Ludwig H, Bolejack V, Crowley J, Blade J, San Miguel J, Kyle RA et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010; 28: 1599-1605.
12. Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 2011; 16: 1600-1603.
13. Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19: 3350-3356. (Pubitemid 32642187)
14. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118: 4346-4352.
15. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007; 92: 1415-1418. (Pubitemid 350144161)
16. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782-1791.
17. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
18. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473. (Pubitemid 44264086)
19. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
20. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328. (Pubitemid 41098849)
21. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549.
22. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. Highdose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85-93.
23. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA et al. Riskadjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025-1031. (Pubitemid 40028833)
24. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. Highdose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-1093. (Pubitemid 47443213)
25. Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S, Buadi F et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008; 49: 36-41. (Pubitemid 351146880)
26. Tapan U, Seldin DC, Finn KT, Fennessey S, Shelton A, Zeldis JB et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood 2010; 116: 5071-5072.
27. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118: 865-873.
28. Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 2010; 116: 4777-4782.
29. Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol 2012; 91: 89-92.
30. Sanchorawala V, Finn KT, Fennessey S, Shelton A, Doros G, Zeldis JB et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood 2010; 116: 1990-1991.
31. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457-464. (Pubitemid 46105938)
32. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295-298. (Pubitemid 351397721)
33. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone /-thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007; 139: 224-233.
34. Landau H, Hassoun H, Bello C, Hoover E, Riedel ER, Nimer SD et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid 2011; 18(Suppl 1): 130-131.
35. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone (CYBORD) produces rapid and complete hematological response in patients with AL amyloidosis. Blood 2012; 119: 4391-4394.
36. Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B et al. Thalidomidedexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009; 113: 3435-3442.
37. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
38. Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G et al. Short and longterm outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Ann Hematol 2010; 89: 579-584.
39. Abraham RS, Ballman KV, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 2005; 105: 794-803. (Pubitemid 40070767)
40. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009; 94: 380-386.
41. Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008; 111: 4700-4705.